Latest Conference

Nicola F. Tavella, MPH, dives into his team's research on postpartum depression and unplanned cesarean delivery, which was presented at SMFM's 2025 Pregnancy Meeting.

Timely diagnosis of gestational diabetes is crucial for optimal maternal and fetal health, but a recent study highlights demographic disparities in screening delays and the need for further research on potential health impacts.

A new study links first-trimester hemorrhage and anemia to a higher placenta accreta spectrum risk, emphasizing early screening and non-traditional risk factors.

AI-assisted software improves clinicians' detection of congenital heart defects in prenatal ultrasounds, enhancing accuracy, confidence, and speed, according to a study presented at SMFM's Annual Pregnancy Meeting.

Daniel L. Kuhr, MD, maternal fetal medicine fellow at Mount Sinai, discusses the role of neighborhood-level indices in predicting spontaneous preterm birth risk and why individual patient characteristics remain the key factor.

A new randomized control trial reveals that barbed sutures significantly reduce blood loss during hysterotomy, offering valuable insights for improving clinical outcomes in obstetric surgery.

A new study presented at the SMFM 2025 Pregnancy Meeting found that homicide and suicide are the leading causes of maternal death in the United States.

A new study explores the potential link between antiretroviral therapy, specifically integrase inhibitors, and fetal biometric measurements, shedding light on possible pregnancy complications.

Artificial intelligence-powered ultrasound analysis is enhancing the early detection of congenital heart defects, improving diagnostic accuracy, physician confidence, and neonatal outcomes.

In a recent study, significantly more urology websites contained information about male sexual dysfunction when compared to the availability of female sexual dysfunction information on ob-gyn websites.

In a recent study presented at the 25th Annual Fall Scientific Meeting of SMSNA, similar diagnosing success was reported between self-diagnosis and diagnosis from a health care provider for vaginismus.

Matthew Nudy, MD, discusses his team's findings on hormone therapy and cardiovascular effects at the 2024 Annual Meeting of the Menopause Society.

Learn how self-advocacy, preparation, and collaboration with doctors can help women gain control over their health and live more fully, free from stigma and shame.

Discover how deepening understanding and providing vetted resources can empower women to reclaim their wellness and navigate the powerful impacts of menopause with confidence.

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

A new study highlights gestational hypertension as a significant predictor of cardiovascular disease in menopausal women, challenging previous assumptions about preeclampsia’s role.

Vanessa Muñiz presents research comparing clinical hypnosis and cognitive behavioral therapy for treating hot flashes, revealing that hypnosis significantly reduces frequency and improves quality of life.

Stephanie Faubion, MD, MBA, medical director of the Menopause Society, shares details from her presentation on hormone therapy at the 2024 Annual Meeting of The Menopause Society.

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

Low rates of hormone therapy use have been reported among midlife women, stagnating after decreases in the immediate aftermath of the Women’s Health Initiative.

A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.

In this video from The Menopause Society Annual Meeting, Lauren Streicher, MD, talks about what to ask your patients about sexual function.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 23% of patients with breast arterial calcifications on a mammogram had atherosclerotic cardiovascular disease, vs 13.9% without.